secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001171843-25-001900
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)
--------------------------------------------------------------------------------

- ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.
- One complete response in combo arm; progressive disease rate 16.2% vs 42.1%.
- Secondary endpoints (PFS, OS, DoR) not yet mature; expected Q4 2025 after 80% event threshold.
- Safety consistent with prior studies; DMC recommended continuation after four reviews.
- BTC affects ~23,000 US patients annually; ~85% lack approved second-line targeted therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/0001171843-25-001900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/f8k_040125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer